肝癌细胞转移与PI3K-Akt-PAK1通路的相关性研究

doi:10.3969/j.issn.1672-5069.2017.03.013

Abstract

Abstract: Objective Based on relevant database data,we tried to explore the importance of PI3K/Akt/PAK1 signaling pathway to HCC metastasis and provide an effective molecular marker for the prevention of HCC. Methods From GES364 data sets of GEO in the NCBI database,we searched the materials about the PI3K/Akt/PAK1 expression in intrahepatic spread （IHS）,entrahepatic metastasis （EHM）,non-metastasis （NM） and normal livers （N）. Results The expression of PAK1 and MMP-9 were up-regulated in IHS and EHM group（P<0.0001） as compared with those in normal liver and NM group; the expression of AKT （1/2） and Girdin were up-regulated in the IHS,EHM and NM group（P<0.05） as compared with in normal liver;in the EHM group,the expression of AKT2 was positively correlated to PAKI（r=0.5679,P=0.0013）. Conclusions The up-regulation of PAK1 and MMP-9 could promote the spread and metastasis of HCC cells,the increased expression and activities of AKT are crucial for metastasis of liver cancer,and the PI3K/AKT/PAK1 signaling pathway is closely related to the development and metastasis in patients with HCC.

Key words: Hepatocellular carcinoma, Metastasis, PAK1, AKT

Zhang Lei, Wang Lin, Geng Zhimin, et al.. Expression of PI3K-Akt-PAK1 pathway in the process of metastasis of hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 307-311.

References

[1] Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma. Lancet,2003,362:1907.
[2] Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002. CA Cancer J Clin,2005,55:74.
[3] Chen CJ,Yu MW,Liaw YF.Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol,1997,12:S294.
[4] Thorgeirsson SS,Grisham JW.Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet,2002,31:339.
[5] Bruix J,Boix L,Sala M,et al.Focus on hepatocellular carcinoma. Cancer Cell,2004,5:215.
[6] Laurent-Puig P,Legoix P,Bluteau O,et al.Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology,2001,120:1763.
[7] Wang XM,Yang LY,Guo L,et al.p53-induced RINGH2 protein,a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer,2009,115:4554.
[8] Lau WY,Lai EC.Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int,2008,7:237.
[9] Manser E,Leung T,Salihuddin H,et al.A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature,1994,367:40.
[10] Knaus UG,Morris S,Dong HJ,et al.Regulation of human leukocyte p21-activated kinases through G proteinecoupled receptors. Science,1995,269:221.
[11] Martin GA,Bollag G,McCormick F,et al. A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. EMBO J,1995,14:1970.
[12] Bagrodia S,Taylor SJ,Jordon KA,et al.A novel regulator of p21-activated kinases. J Biol Chem,1998,273:23633.
[13] Kumar R,Vadlamudi RK.Emerging functions of p21-activated kinases in human cancer cells. J Cell Physiol,2002,193:133.
[14] Bokoch GM.Biology of the p21-activated kinases. Annu Rev Biochem,2003,72:743.
[15] Hofmann C,Shepelev M,Chernoff J.The genetics of Pak. J Cell Sci,2004,117:4343.
[16] Kumar R,Gururaj AE,Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer,2006,6:459.
[17] Wells CM,Jones GE.The emerging importance of group II PAKs. Biochem J,2010,425:465.
[18] Jaffer ZM,Chernoff J. p21-activated kinases:three more join the Pak. Int J Biochem Cell Biol,2002,34:713.
[19] Zhao ZS,Manser E.PAK and other Rho-associated kinaseseeffectors with surprisingly diverse mechanisms of regulation. Biochem J,2005,386:201.
[20] Arias-Romero LE,Chernoff J.A tale of two Paks. Biol Cell,2008,100:97.
[21] Carter JH,Douglass LE,Deddens JA,et al.Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res,2004,10:3448.
[22] Bekri S,Adelaide J,Merscher S,et al.Detailed map of a region commonly amplified at 11q13>q14 in human breast carcinoma. Cytogenet Cell Genet,1997,79:125.
[23] Siu MK,Wong ES,Chan HY,et al.Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer:effects on prognosis and cell invasion. Int J Cancer,2010,127:21.
[24] Ching YP,Leong VY,Lee MF,et al.P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res,2007,67:3601.
[25] Vadlamudi RK,Adam L,Wang RA,et al.Regulatable expression of p21-activated kinase-1 promotes anchorageindependent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem,2000,275:36238.
[26] Adam L,Vadlamudi R,Mandal M,et al.Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem,2000,275:12041.
[27] Engelman JA,Luo J,Cantley LC.The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet,2006,7(8):606-619.
[28] Bellacosa A,Kumar CC,Cristofano AD,et al.Activation of AKT kinases in cancer:implications for therapeutic targeting. Adv Cancer Res,2005,94:29-86.
[29] Iyer SC,Gopal A,Halagowder D.Myricetin induces apoptosis by inhibiting P21 activated kinase 1(PAK1) signaling cascade in hepatocellular carcinoma. Mol Cell Biochem,2015,407(1-2):223-237.
[30] Li YY,Li J,Chen L.Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma. Tumour Biol,2014,35(4):3809-3817.
[31] Huynh N,Kevin HL,Baldwin GS,et al.P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK-and AKT-dependent pathways. Biochim Biophys Acta,2010,1803:1106-1113.
[32] Balmanno K,Chell SD,Gillings AS,et al.Intrinsic resistance to the MEK1/2 inhibitorAZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer,2009,125:2332-2341.

Expression of PI3K-Akt-PAK1 pathway in the process of metastasis of hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Ouyang Shi, Chen Xiaoping, Cheng Tao, et al.. Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 940-946.